Development Reports and Information Sample Clauses

The 'Development Reports and Information' clause requires one party, typically the developer, to provide regular updates and relevant information about the progress of a project to the other party. This may include periodic written reports, status updates, or access to documentation and records related to the development process. By mandating the sharing of timely and accurate information, this clause ensures transparency, enables effective monitoring of project milestones, and helps address issues proactively before they escalate.
Development Reports and Information. Gen-Probe and Chiron shall keep each other informed of their progress under the Development Programs for Clinical Diagnostic Assays and Clinical Diagnostic Instruments. The parties shall develop reasonable procedures for requesting and delivering copies of such records to each other as may be necessary for the performance of the Development Programs for Clinical Diagnostic Assays and Clinical Diagnostic Instruments. Within thirty (30) days following the end of each calendar quarter during the term of the Development Programs for Clinical Diagnostic Assays and Clinical Diagnostic Instruments, and within thirty (30) days following the expiration or termination of such Development Programs, Gen-Probe and Chiron each shall prepare and provide to the other party a reasonably detailed written summary report which shall describe the work performed by such party to date under such Development Programs.
View SourceView Similar (2)
Development Reports and Information. Gen-Probe and Novartis each shall keep the other informed of the progress of such party under the Development Programs for Blood Screening Assays and Blood Screening Instruments.
View SourceView Similar (2)
Development Reports and Information. Gen-Probe and Chiron each shall keep the other informed of the progress of such party under the Development Programs for Blood Screening Assays and Blood Screening Instruments. Within thirty (30) days following the end of each calendar quarter during the term of the Development Programs for Blood Screening Assays and Blood Screening Instruments, and within thirty (30) days following the expiration or termination of such Development Programs, Gen-Probe and Chiron each shall prepare and provide to the other party a reasonably detailed written summary report which shall describe the work performed by such party to date under such Development Programs. ***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
View SourceView Similar (2)
Development Reports and Information. ▇▇▇▇▇▇▇-▇▇▇▇▇ shall keep Ixsys informed as to the progress of the preclinical and clinical development and testing of all Products which ▇▇▇▇▇▇▇-▇▇▇▇▇ elects to develop and the preparing, filing and obtaining of the approvals necessary for marketing of all Products. Within thirty (30) days following each April 30, August 31 and December 31 following the commencement of preclinical development of a Product undertaken by ▇▇▇▇▇▇▇-▇▇▇▇▇, ▇▇▇▇▇▇▇-▇▇▇▇▇ shall provide to Ixsys a written report which shall summarize the progress of the development and testing of Products in preclinical development and clinical trials. In addition, ▇▇▇▇▇▇▇-▇▇▇▇▇ shall provide to Ixsys a minimum of six (6) months advance written notice of the contemplated filing of an Investigational New Drug application ("IND") with the FDA in the United States (or its equivalent in any other country), a written report which shall summarize all other regulatory submissions prior to the date of such submissions, and written notice of all approvals obtained promptly after obtaining such approvals.
View SourceView Similar (2)
Development Reports and Information. From and after the Effective Date, within [**] following the end of each [**] prior to Completion of the Arvinas Clinical Trials Transfer, Arvinas shall provide to the JSC (or, Novartis, if the JSC has been disbanded) (x) a reasonably detailed written report of the Arvinas Clinical Trial Activities conducted during such [**], as applicable, which report shall contain sufficient detail to enable the JSC (or Novartis, if the JSC has been disbanded) to assess Arvinas’ compliance with the Arvinas Development Plan [**] and this Agreement; and (y) access to or copies of any final written reports related to such Arvinas Clinical Trial Activities (or results of analyses thereof) as may be prepared by or on behalf of Arvinas or its Affiliates. Upon the reasonable request of Novartis from time to time, Arvinas shall make appropriate personnel with knowledge of the Arvinas Clinical Trial Activities available to Novartis to discuss such activities and provide or make available to Novartis all Data arising from the Arvinas Clinical Trial Activities in its possession or Control and not previously provided or made available.
View Source
Development Reports and Information. Following the expiration of the Research Program and during the Development Program, Bayer shall keep Immune Response informed as to the progress of the clinical development of each Product and the progress in preparing, filing and obtaining of the necessary marketing and pricing approvals to commercially sell and use the Product. Within thirty (30) days following the end of each June and December during the term of the Development Program, Bayer shall prepare, and provide to Immune Response, a summary written report which shall describe the progress of the clinical development and testing of Products in such clinical trials, the status of manufacturing such Product and the preparations to manufacture and supply such Product for any future clinical development and commercial sale, all regulatory filings and submissions made and all approvals obtained.
View Source
Development Reports and Information. From and after the Effective Date, within [***], Licensor shall provide to the DC (or, Novartis, if the DC has been disbanded): [***]. Upon the reasonable request of Novartis from time to time, Licensor shall make appropriate personnel with knowledge of the Licensor Clinical Trial Activities available to Novartis to discuss such activities; provided that Novartis shall reimburse Licensor for such assistance in accordance with Section 9.8 (Licensor Assistance), excluding DC meetings pursuant to Section 3.2 (Development Committee). 4.3 Regulatory Matters. (a) Regulatory Submissions by Licensor. (i) Notwithstanding any other provision of this Agreement, without Novartis’ prior written consent, neither Licensor nor its Affiliates shall submit or file any Regulatory Materials or otherwise communicate with any Regulatory Authority regarding Licensed Compounds or Licensed Products or the Exploitation thereof (including any Clinical Trial or other Development activities) other than regarding matters specifically related to the Licensor Clinical Trial Activities and in accordance with this Agreement. (b) Regulatory Materials Received by Licensor. Licensor shall provide Novartis with: [***], in each case ((i) and (ii)), within [***] of their receipt or production of the foregoing, as applicable. If such [***], but not later than [***] after receipt of such correspondence.
View Source
Development Reports and Information. Gen-Probe and Chiron each shall keep the other informed of the progress of such party under the Development Programs for Blood Screening Assays and Blood Screening Instruments. Within thirty (30) days following the end of each calendar quarter during the term of the Development Programs for Blood Screening Assays and Blood Screening Instruments, and within thirty (30) days following the expiration or termination of such Development Programs, Gen-Probe and Chiron each shall prepare and provide to the other party a reasonably detailed written summary report which shall describe the work performed by such party to date under such Development Programs.
View Source

Related to Development Reports and Information

  • Reports and Information Contractor shall at such times and in such forms as the City may require furnish the City such periodic reports as it may request pertaining to the work or services undertaken pursuant to this Agreement, the costs and obligations incurred or to be incurred in connection therewith, and any other matters are covered by this Agreement as specified in Exhibit A and Exhibit E.

  • Other Reports and Information Borrower shall advise Lender promptly, in reasonable detail, of: (a) any Lien, other than Permitted Encumbrances, attaching to or asserted against any of the Collateral or any occurrence causing a material loss or decline in value of any Collateral and the estimated (or actual, if available) amount of such loss or decline; (b) any material change in the composition of the Collateral; and (c) the occurrence of any Default or other event which has had or could reasonably be expected to have a Material Adverse Effect. Borrower shall, upon request of Lender, furnish to Lender such other reports and information in connection with the affairs, business, financial condition, operations, prospects or management of Borrower or any other Credit Party or the Collateral as Lender may request, all in reasonable detail.

  • Background Information The Adviser has entered into an Investment Adviser's Agreement with the Fund ("Investment Adviser's Agreement"). Pursuant to the Investment Adviser's Agreement, the Adviser has agreed to render investment advisory and certain other management services to all of the funds of the Fund, and the Fund has agreed to employ the Adviser to render such services and to pay to the Adviser certain fees therefore. The Investment Adviser's Agreement recognizes that the Adviser may enter into agreements with other investment advisers who will serve as fund managers to the funds.

  • Access and Information The Company, on the one hand, and Parent and Acquisition Corp., on the other hand, shall each afford to the other and to the other’s accountants, counsel and other representatives full access during normal business hours throughout the period prior to the Effective Time to all of its properties, books, contracts, commitments and records (including but not limited to tax returns) and during such period, each shall furnish promptly to the other all information concerning its business, properties and personnel as such other party may reasonably request, provided that no investigation pursuant to this Section 6.01 shall affect any representations or warranties made herein. Each party shall hold, and shall cause its employees and agents to hold, in confidence all such information (other than such information that (a) is already in such party’s possession or (b) becomes generally available to the public other than as a result of a disclosure by such party or its directors, officers, managers, employees, agents or advisors or (c) becomes available to such party on a non-confidential basis from a source other than a party hereto or its advisors, provided that such source is not known by such party to be bound by a confidentiality agreement with or other obligation of secrecy to a party hereto or another party until such time as such information is otherwise publicly available; provided, however, that (i) any such information may be disclosed to such party’s directors, officers, employees and representatives of such party’s advisors who need to know such information for the purpose of evaluating the transactions contemplated hereby (it being understood that such directors, officers, employees and representatives shall be informed by such party of the confidential nature of such information), (ii) any disclosure of such information may be made as to which the party hereto furnishing such information has consented in writing and (iii) any such information may be disclosed pursuant to a judicial, administrative or governmental order or request; provided, further, that the requested party will promptly so notify the other party so that the other party may seek a protective order or appropriate remedy and/or waive compliance with this Agreement and if such protective order or other remedy is not obtained or the other party waives compliance with this provision, the requested party will furnish only that portion of such information that is legally required and will exercise its best efforts to obtain a protective order or other reliable assurance that confidential treatment will be accorded the information furnished. If this Agreement is terminated, each party will deliver to the other all documents and other materials (including copies) obtained by such party or on its behalf from the other party as a result of this Agreement or in connection herewith, whether so obtained before or after the execution hereof.

  • Data and Information 14.1 The Contractor shall have the right to use, and shall have access to, all geological, geophysical, drilling, well production, well location maps and other information held by the Republic related to the Contract Area in consideration of the payment of the required fees. 14.2 The Contractor shall promptly provide the Minister, free of cost, with all data obtained as a result of Hydrocarbons Operations under this Contract, including seismic data, geological, geophysical, geochemical, petro-physical, engineering, well logs, maps, magnetic tapes, cores, cuttings and production data, as well as all interpretative and derivative data, including reports, analyses, interpretations and evaluations prepared in respect of Hydrocarbons Operations. 14.3 The Republic shall have title to all original data and information resulting from Hydrocarbons Operations under this Contract, including but not limited to geological, geophysical, petro-physical and engineering data, well logs and completion status reports, and any other data that the Contractor or anyone acting on its behalf may compile or obtain during the term of this Contract. The Contractor is entitled to retain and use a copy of all such data, subject to the provisions of this Article 14. 14.4 The Contractor acknowledges the proprietary rights of the Republic in all data and information referred to in this Article 14 and agrees to treat all such data and information as confidential and to comply with applicable laws and regulations with respect to the storage and any transport or export out of the Republic of any such data and information. 14.5 The Contractor may disclose such information to its employees to the extent required for efficient conduct of Hydrocarbons Operations, provided such individuals have signed or otherwise be subject to an undertaking relating to the confidentiality of the same information as part of their employment contract, or to Affiliates and consultants, or to bona fide prospective assignees of rights under this Contract or to banks or financial institutions from which finance is sought, provided that the Contractor obtains from such entities, prior to disclosure, a written confidentiality undertaking. In the case of disclosure to prospective assignees, any disclosure of such information shall require the prior written consent of the Minister, which consent shall not be unreasonably withheld. 14.6 The Contractor may disclose information as and to the extent required by a regulatory or judicial authority having proper jurisdiction over the Contractor, provided that the Minister is first notified of such disclosure and of the information so disclosed. 14.7 The Contractor’s obligation of confidentiality under this Article shall be of a continuing nature and shall not be cancelled by the expiration, suspension or termination of this Contract, or by any transfer or assignment of interest under this Contract.